Choroidal neovascularisation in pathologic myopia: intravitreal ranibizumab versus bevacizumab - a randomised controlled trial

a Sapienza University of Rome (Italy)0 个研究点目标入组 40 人开始时间: 2009年10月1日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Both males and females, no age limit
•2. Pathologic myopia, defined as axial length more than 26.5 mm
•3. Subfoveal or juxtafoveal choroidal neovascularisation (CNV), CNV was classified as juxtafoveal if the lesion was closer than 200 microns but not under the geometric centre of the foveal avascular zone
•4. Evidence of leakage from CNV on fluorescein angiography

•1. Prior treatment for CNV
•2. Other ocular diseases that could affect the visual acuity
•3. Angioid streaks
•5. Choroiditis
•6. Hereditary diseases in the study or the fellow eye
•7. Aphakia
•8. Previous vitreoretinal surgery
•9. Prior history of bleeding diathesis
•10. Prior cerebrovascular accident
•11. Pulmonary embolus or deep venous thrombosis
•12. Myocardial infarction or uncompensated coronary artery disease within the past 6 months
•13. Major surgery within the prior 6 weeks
•14. Ongoing uncontrolled hypertension

发起方

a Sapienza University of Rome (Italy)